Clinical Trial Update: A Single-dose Study to Investigate the Pharmacokinetics of Intravenous FEP-TAZ in Patients With Renal Impairment [Phase 1]

View source ↗

Summary

Phase 1, single-dose pharmacokinetic study of intravenous FEP-TAZ in patients with renal impairment has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Impairment

Drugs mentioned

• FEP-TAZ (cefepime-tazobactam)

Snippet

Sponsor: Wockhardt | Conditions: Renal Impairment | Phase 1 | Status: COMPLETED